Confirming The Sitaxsentan Dose In Patients Undergoing Heart Surgery

• Cardiac Surgery Subjects
• Subjects Undergoing CABG and/or Cardiac Valve Replacement

• Drug: sitaxsentan (Thelin)
  
  sitaxsentan (1.0 mg/kg) will begin immediately following cross-clamp release and 12 hours post-CPB.
  Other Names:
  

  • sitaxsentan
  • Thelin
• Drug: sitaxsentan (Thelin)
  
  sitaxsentan (2.0 mg/kg) will begin immediately following cross-clamp release and 12 hours post-CPB.
  Other Names:
  

  • sitaxsentan
  • Thelin
• Drug: Placebo
  
  Placebo will begin immediately following cross-clamp release and 12 hours post-CPB.

• Experimental: sitaxsentan (1.0 mg/kg)
  
  Intervention: Drug: sitaxsentan (Thelin)
• Experimental: sitaxsentan (2.0 mg/kg)
  
  Intervention: Drug: sitaxsentan (Thelin)
• Placebo Comparator: Placebo
  
  Intervention: Drug: Placebo

Inclusion Criteria:

• Has been identified for coronary artery bypass grafting (CABG), aortic and/or mitral valve replacement, or combined CABG and cardiac valve replacement procedures that require cardiopulmonary bypass (CPB).

Exclusion Criteria:

• Requires an emergent or "emergency" CABG and/or cardiac valve replacement.